The inaugural ELRIG Drug Discovery USA 2026 will focus on emerging multifunctional small molecule and biologic approaches to difficult-to-drug targets.
Recent advances in chemical biology and protein engineering are expanding the boundaries of which proteins can be modulated pharmacologically. Multifunctional small molecules (such as molecular glues, targeted protein degraders, and allosteric modulators) are enabling precise control over protein stability, localization, and activity, often by exploiting endogenous cellular pathways.
In parallel, novel biologic modalities, including engineered antibodies, multi-specific binders, peptide scaffolds, nucleotide and RNA therapeutics, offer complementary strategies to engage complex or transient target surfaces with high affinity and specificity. Collectively, these approaches are reshaping early‑stage drug discovery by providing versatile platforms to modulate challenging targets through mechanisms beyond simple inhibition.
Furthermore, hybrid strategies that integrate small molecules with biologics, such as antibody–drug conjugates (ADCs) and chemically enhanced biologics, are demonstrating synergistic potential. Together, these emerging technologies highlight a rapidly evolving therapeutic landscape in which difficult-to-drug targets are increasingly accessible, opening new avenues for disease intervention and precision medicine. Continued innovation in molecular design, delivery, and mechanistic understanding will be critical to fully realize the promise of these next‑generation modalities.
This free-to-attend event takes place at Pfizer in Cambridge, MA, from 16–17 June.
